Daiichi Sankyo’s CLEAR Taiwan Study: A New Chapter in Lipid-Lowering Therapy

Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study.

Study Overview: The CLEAR Taiwan Study, officially titled A Multicenter, Prospective, Phase IV, Interventional Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan, aims to assess the effectiveness and safety of bempedoic acid in Taiwanese patients. This study is significant as it addresses the gap in data regarding East Asian populations, particularly in Taiwan, for managing cardiovascular disease risk through lipid-lowering therapy.

Intervention/Treatment: The study tests bempedoic acid, a novel nonstatin lipid-lowering agent, administered as a 180 mg tablet once daily for 12 weeks. It is intended to lower cholesterol levels and reduce cardiovascular risks, particularly in patients intolerant to statins.

Study Design: This interventional Phase IV study employs a single-group model with no masking. Its primary purpose is treatment, focusing on evaluating the drug’s effectiveness and safety in a real-world Taiwanese setting.

Study Timeline: The study began on April 6, 2025, with its primary completion and last update submitted on December 5, 2025. These dates are crucial as they mark the study’s progression and the availability of updated information.

Market Implications: The completion of this study could positively impact Daiichi Sankyo’s stock performance by expanding the market for bempedoic acid in Asia, particularly if results show favorable safety and efficacy. This could enhance investor sentiment, especially as the demand for effective lipid-lowering therapies grows. Competitors in the lipid-lowering market may need to adjust strategies in response to these findings.

The study is completed, with further details available on the ClinicalTrials portal.

To learn more about DSKYF’s potential, visit the Daiichi Sankyo Company drug pipeline page.